Kenvue Inc. (NYSE:KVUE) Shares Sold by Accel Wealth Management

Accel Wealth Management cut its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.9% in the 4th quarter, Holdings Channel reports. The fund owned 19,489 shares of the company’s stock after selling 583 shares during the period. Accel Wealth Management’s holdings in Kenvue were worth $420,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of KVUE. Envestnet Asset Management Inc. acquired a new stake in shares of Kenvue during the second quarter valued at about $1,387,000. Cetera Investment Advisers acquired a new stake in shares of Kenvue during the second quarter valued at about $416,000. Citigroup Inc. bought a new position in shares of Kenvue during the second quarter worth about $57,000. Osaic Holdings Inc. bought a new position in shares of Kenvue during the second quarter worth about $144,000. Finally, Northern Trust Corp bought a new position in shares of Kenvue during the second quarter worth about $1,244,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

KVUE has been the topic of several research analyst reports. JPMorgan Chase & Co. reduced their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Royal Bank of Canada reduced their price target on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. UBS Group increased their price target on shares of Kenvue from $20.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 19th. Finally, The Goldman Sachs Group initiated coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.42.

Kenvue Price Performance

NYSE KVUE traded up $0.52 during trading hours on Wednesday, reaching $21.45. The company’s stock had a trading volume of 13,286,504 shares, compared to its average volume of 17,550,154. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The business has a 50-day simple moving average of $20.00 and a 200 day simple moving average of $20.25. Kenvue Inc. has a 52 week low of $17.82 and a 52 week high of $27.80.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.78 billion. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. As a group, equities research analysts expect that Kenvue Inc. will post 1.17 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Shareholders of record on Wednesday, February 14th were paid a $0.20 dividend. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 annualized dividend and a dividend yield of 3.73%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.